These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7758056)

  • 1. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders.
    Einarson TR; Arikian S; Sweeney S; Doyle J
    Clin Ther; 1995; 17(1):136-53. PubMed ID: 7758056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom.
    Freeman H; Arikian S; Lenox-Smith A
    Pharmacoeconomics; 2000 Aug; 18(2):143-8. PubMed ID: 11067648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK.
    Lenox-Smith A; Conway P; Knight C
    Pharmacoeconomics; 2004; 22(5):311-9. PubMed ID: 15061681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacoeconomic evaluation of major depressive disorder (Italy).
    Casciano J; Arikian S; Tarride JE; Doyle JJ; Casciano R
    Epidemiol Psichiatr Soc; 1999; 8(3):220-31. PubMed ID: 10638040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomics of antidepressants in moderate-to-severe depressive disorder in Colombia.
    Machado M; Lopera MM; Diaz-Rojas J; Jaramillo LE; Einarson TR;
    Rev Panam Salud Publica; 2008 Oct; 24(4):233-9. PubMed ID: 19133171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical review of selected pharmacoeconomic analyses of antidepressant therapy.
    Conner TM; Crismon ML; Still DJ
    Ann Pharmacother; 1999 Mar; 33(3):364-72. PubMed ID: 10200863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants in major depressive disorder in Italy.
    Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
    Adv Ther; 2013 Jul; 30(7):697-712. PubMed ID: 23929174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of antidepressive agents: a systematic critique of experimental and observational studies.
    Barbui C; Percudani M; Hotopf M
    J Clin Psychopharmacol; 2003 Apr; 23(2):145-54. PubMed ID: 12640216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder.
    Burke MJ; Silkey B; Preskorn SH
    J Clin Psychiatry; 1994 Sep; 55 Suppl A():42-52; discussion 53-4, 98-100. PubMed ID: 7961542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression.
    Nguyen KH; Gordon LG
    Value Health; 2015 Jul; 18(5):597-604. PubMed ID: 26297087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.
    Sussman M; Yu J; Kamat SA; Hartry A; Legacy S; Duffy R; Aigbogun MS
    J Affect Disord; 2017 Jan; 207():54-62. PubMed ID: 27693466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of depression: the implications for managed care--roundtable discussion: Part 2.
    Arikian S; Casciano J; Kang-Cipolla L; Vodoor M; Grubin M; Clark D; Waugh W; Kelsey J; Osborn LW
    Manag Care Interface; 2000; Suppl B():19-25, 32. PubMed ID: 11183021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model.
    Ramsberg J; Asseburg C; Henriksson M
    PLoS One; 2012; 7(8):e42003. PubMed ID: 22876296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression.
    Nuijten MJ; Hardens M; Souêtre E
    Pharmacoeconomics; 1995 Aug; 8(2):159-68. PubMed ID: 10155610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 2: Cost-effectiveness analyses.
    Henry JA; Rivas CA
    Pharmacoeconomics; 1997 Jun; 11(6):515-37. PubMed ID: 10168093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the cost effectiveness of antidepressant treatment in primary care.
    Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D
    Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacoeconomic study of the management of major depression: patients in a TennCare HMO.
    Smith W; Sherrill A
    Med Interface; 1996 Jul; 9(7):88-92. PubMed ID: 10159282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment.
    Jönsson B; Bebbington PE
    Br J Psychiatry; 1994 May; 164(5):665-73. PubMed ID: 7921718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.